Co-Administration of Resveratrol and Lipoic Acid, or Their Synthetic Combination, Enhances Neuroprotection in a Rat Model of Ischemia/Reperfusion

Monique C. Saleh¹, Barry J. Connell¹, Desikan Rajagopal³, Bobby V. Khan¹,³, Alaa S. Abd-El-Aziz², Inan Kucukkaya², Tarek M. Saleh¹*

¹Department of Biomedical Sciences, Atlantic Veterinary College, University of Prince Edward Island, Charlottetown, P.E.I., Canada, ²Department of Chemistry, University of Prince Edward Island, Charlottetown, P.E.I., Canada, ³Carmel BioSciences Inc., Atlanta, Georgia, United States of America

Abstract

The present study demonstrates the benefits of combinatorial antioxidant therapy in the treatment of ischemic stroke. Male Sprague-Dawley rats were anaesthetised and the middle cerebral artery (MCA) was occluded for 30 minutes followed by 5.5 hours of reperfusion. Pretreatment with resveratrol 30 minutes prior to MCA occlusion resulted in a significant, dose-dependent decrease in infarct volume (p<0.05) compared to vehicle-treated animals. Neuroprotection was also observed when resveratrol (2 × 10⁻³ mg/kg; iv) was administered within 60 minutes following the return of blood flow (reperfusion). Pretreatment with non-neuroprotective doses of resveratrol (2 × 10⁻³ mg/kg) and lipoic acid (LA; 0.005 mg/kg) in combination produced significant neuroprotection as well. This neuroprotection was also observed when resveratrol and LA were administered 15 minutes following the onset of MCA occlusion. Subsequently, we synthetically combined resveratrol and LA in both a 1:3 (UPEI-200) and 1:1 (UPEI-201) ratio, and screened these new chemical entities in both permanent and transient ischemia models. UPEI-200 was ineffective, while UPEI-201 demonstrated significant, dose-dependent neuroprotection. These results demonstrate that combining subthreshold doses of resveratrol and LA prior to ischemia-reperfusion can provide significant neuroprotection likely resulting from concurrent effects on multiple pathways. The additional protection observed in the novel compound UPEI 201 may present opportunities for addressing ischemia-induced damage in patients presenting with transient ischemic episodes.

Introduction

Despite ongoing advances in the arena of stroke research, the worldwide consequences of death and disability remain considerable and delivery of successful therapeutics continues to present a challenge. The application of combinatorial drug therapy in treating stroke has become increasingly attractive in recent years. As researchers uncover the complexity of disease progression following stroke which includes both immediate as well as delayed neuronal effects at multiple levels [1], it has become evident that multi-targeted drug therapy may hold more promise in the treatment and/or prevention of stroke than conventional single class drug regimens. In addition, there is evidence that some drug combinations display pharmaceutical potentiation (ie synergism) which optimistically translates into lower doses, fewer adverse side effects and an extended treatment window. Treatment outcomes for ischemic events involves the reestablishment of blood flow to compromised tissue, with the reintroduction of oxygen transiently adding to the injury due to generation of inflammatory mediators and toxic levels of oxidative free radicals [2] culminating in lipid peroxidation, protein synthesis arrest, and ultimately cell death [3]. Successful treatment options are therefore required to address several critical mediators of neuronal death simultaneously.

With the increasing popularity of natural products, science has sought to exploit the medicinal potential of common extracts as is evident in the growing literature of natural product drug discovery. In the current study, we test 2 novel compounds combining resveratrol (3, 5, 4’-trihydroxystilbene), a naturally-occurring component of grapes, and 2- lipoic acid (LA), a potent anti-oxidant found in common foods, for neuroprotective effects in 2 animal models of ischemic stroke. Separately, resveratrol and LA possess potent anti-oxidant and anti-inflammatory activities and have been shown to produce neuroprotection in several animal models of neurological disease via complementary pathways [4][5].

Resveratrol possesses multiple biological activities [6][7], including being a potent antioxidant [8] and anti-inflammatory [9] agent. These therapeutic uses of resveratrol have led researchers to investigate its protective effects in several animal models of neurological disease, particularly those with unknown
etiology, or where inflammation and oxidative stress may play a role in the pathogenesis. Consequently, resveratrol has shown promise as a neuroprotectant in animal models of cerebral ischemia through its ability to attenuate ischemia-induced cell death [10].

Also a powerful antioxidant, α-lipoic acid (LA) is characterized by high reactivity towards free radicals [11] and demonstrates potent neuroprotective effects in several animal models of stroke including models of reperfusion injury [12], [13], [14], [15], [16], [17]. Further, the co-administration of LA with other compounds has been shown to enhance the protective effect of the drug in various animal models of pathology [18], [19], [20], [21], [22]. Our own research has shown that co-administration of non-protective (sub-threshold) doses of both LA and apocynin, an NADPH oxidase inhibitor, provided significant neuroprotection against ischemic injury [23].

Figure 1. Dose-dependent effect of resveratrol on infarct volume following transient ischemia/reperfusion. (A) Representative photomicrographs of TTC-stained, 1 mm thick coronal slices illustrating the extent of infarct within the prefrontal cortex following pretreatment (30 minutes prior to MCAO; i.v.) with either Vehicle (propylene glycol 4×10⁻³% (v/v)) or Resveratrol (2×10⁻⁷ and 2×10⁻³ mg/kg) following ischemia/reperfusion (tMCAO). (B) Bar graph summarizing the dose-response relationship between increasing doses of resveratrol and infarct size (mm³) calculated from TTC-stained, 1 mm thick coronal sections following tMCAO. Each bar represents the mean ± S.E.M. (n=5–6/group) and * indicates significance (p<0.05) from the vehicle-treated control group.

doi:10.1371/journal.pone.0087865.g001
Thus, the current study investigated the potential for enhanced neuroprotective effects with LA by combining it with resveratrol in a rodent model of acute stroke and reperfusion injury [24]. In addition, the effects of resveratrol and lipoic acid were compared to UPEI-200 and UPEI-201, two novel synthetic compounds linking resveratrol with LA in both a transient occlusion-reperfusion model (tMCAO) as well as in a permanent occlusion model (pMCAO). Lastly, the feasibility of delayed treatment intervention was investigated for all drug combinations.

Methods

Ethics Statement
All experiments were carried out in accordance with the guidelines of the Canadian Council on Animal Care and were approved by the University of Prince Edward Island Animal Care Committee (protocol #11-045 and 13-036).

General Surgical Procedures for in vivo Studies
All experiments were conducted on male Sprague-Dawley rats (250–350 g; Charles Rivers; Montreal, PQ, CAN). For all animals, food and tap water were available ad libitum. Rats were anaesthetized with sodium thiobutabarbital (Inactin; Sigma-Aldrich; St.Louis, MO, USA; 100 mg/kg; ip) and supplemented as needed. For intravenous administration of drugs, a polyethylene catheter (PE-10; Clay Adams, Parsippany, NJ, USA) was inserted into the right femoral vein. An endotracheal tube was inserted to facilitate breathing. Body temperature was monitored and maintained at 37 ± 1°C using a feedback system (Physitemp Instruments; Clifton, NJ, USA).

A separate group of animals were instrumented for the recording of blood pressure and heart rate via an indwelling catheter (PE-50; ; Clay Adams, Parsippany, NJ, USA) placed inside the right femoral artery. Arterial blood pressure was measured with a pressure transducer (Gould P23 ID, Cleveland, OH) connected to a Gould model 2200S polygraph. Heart rate was determined from the pulse pressure using a Gould tachograph (Biotach). These parameters were displayed and analyzed using PolyviewPro/32 data acquisition and analysis software (Grass Technologies, Warwick, RI).

Transient and Permanent Middle Cerebral Artery Occlusions (tMCAO and pMCAO)
We have previously published the detailed methodology for transient occlusion of the middle cerebral artery [24]. Briefly, animals were placed in a David Kopf stereotaxic frame (Tujunga, CA, USA) and the right middle cerebral artery (MCA) approached through a rostra-caudal incision of the skin and frontalis muscle at the approximate level of bregma. Blood flow through the MCA was impeded by the placement of surgical suture behind the MCA at 3 designated positions along the exposed vessel for 30 minutes in the transient model (tMCAO), or left in place for a total of 6 hours in the permanent model (pMCAO). The sutures were positioned such that the middle of each suture applied pressure to the underside of the MCA and impeded blood flow (ischemia) as previously confirmed using laser Doppler flowmetry (OxyFlo, Oxford-Optronix, Oxford, UK) (Connell and Saleh 2010). This 3-point placement of surgical sutures produced a highly reproducible and consistent focal ischemic lesion restricted to the prefrontal cerebral cortex. Blood flow in the tMCAO model was re-established (reperfusion) for an additional 5.5 hours following removal of the sutures.

Drug Preparation
Resveratrol (trans-3,5,4’-trihydroxy stilbene; Sigma Aldrich, St. Louis, MO, USA) stock solutions were prepared in 40% propylene glycol and diluted 10,000X in 0.9% saline. The concentration of propylene glycol in each solution was 4 × 10⁻³% (v/v). Lipoic acid stock solutions were prepared in 40% propylene glycol and diluted 10,000X in 0.9% saline. The concentration of lipoic acid in each solution was 0.005 mg/kg. These solutions were administered intravenously via a polyethylene catheter (PE-10; Clay Adams, Parsippany, NJ, USA) inserted into the right femoral vein.
Synthesis of UPEI-200

The chemical synthesis of UPEI-200 was performed as follows; resveratrol (0.01 M) was combined with 0.05 M LA and 0.04 M of dimethylaminopyridine (DMAP) in 90 ml of anhydrous dichloromethane (CH₂Cl₂). 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI; 0.05 M) was added in small quantities over a period of 2 hours. The entire reaction was performed under nitrogen atmosphere at room temperature. After stirring overnight, the crude mixture of compounds was quickly purified by passing through a silica column following an aqueous work up. The product was again purified on a Chromatotron silica plate using 2 mm pre-coated UV active plate. Appropriate fractions further precipitated urea. The solvent was removed by evaporation in vacuo. The residue was taken up in dichloromethane (CH₂Cl₂) and, if necessary, filtered free of any further precipitated urea. The solvent was removed by evaporation and the crude compound was purified by silica column chromatography (Eluent, Hexanes:Ethylacetate (1:1; yellow oil), Yield; 57%. 1H NMR (300 MHz, Acetone) δ 7.40 (2H, d, J = 8.6 Hz), 7.05–6.79 (4H, m), 6.52 (2H, d, J = 2.1 Hz), 6.25 (1H, t, J = 2.1 Hz), 3.58 (1H, tt, J = 12.7, 6.4 Hz), 3.24–3.04 (2H, m), 2.45 (1H, t, J = 12.3, 6.2 Hz), 2.28 (1H, t, J = 7.2 Hz), 1.95–1.80 (1H, m), 1.79–1.52 (4H, m), 1.45 (2H, ddd, J = 11.1, 7.1, 4.1 Hz).

Synthesis of UPEI-201

Resveratrol (1 mmol) in 20 ml dimethylformamide (DMF) was combined with DMAP (10 mmol) and LA (1 mmol). Dicyclohexylcarbodiimide (DCC; 1 mmol) was added to the reaction mixture at 0°C under nitrogen atmosphere, which is then stirred for 5 min at 0°C and 3 h at 20°C. Precipitated urea is then filtered off and the filtrate evaporated down in vacuo. The residue was taken up in dichloromethane (CH₂Cl₂) and, if necessary, filtered free of any further precipitated urea. The solvent was removed by evaporation and the crude compound was purified by silica column chromatography (Eluent, Hexanes:Ethylacetate (1:1; yellow oil), Yield; 57%. 1H NMR (300 MHz, Acetone) δ 7.40 (2H, d, J = 8.6 Hz), 7.05–6.79 (4H, m), 6.52 (2H, d, J = 2.1 Hz), 6.25 (1H, t, J = 2.1 Hz), 3.58 (1H, tt, J = 12.7, 6.4 Hz), 3.24–3.04 (2H, m), 2.45 (1H, t, J = 12.3, 6.2 Hz), 2.28 (1H, t, J = 7.2 Hz), 1.95–1.80 (1H, m), 1.79–1.52 (4H, m), 1.45 (2H, ddd, J = 11.1, 7.1, 4.1 Hz).

Effect of Resveratrol on tMCAO Model

In the first experiment, resveratrol (2 × 10⁻³ mg/kg; i.v.) or vehicle (propylene glycol 4 × 10⁻³% (v/v); 1 ml/kg; i.v.) at the following intervals during the I/R protocol; 15 minutes (n = 5), 30 minutes (n = 6), 60 minutes (n = 5), 90 minutes (n = 5) mg/kg; i.v.) was administered 30 minutes prior to the onset of MCAO. The sutures were left in place for 30 minutes, followed by 5.5 hours of reperfusion.

The feasibility of extended treatment options was investigated by administering the highest dose of resveratrol (2 × 10⁻³ mg/kg; i.v.) or vehicle (propylene glycol 4 × 10⁻³% (v/v); 1 ml/kg; i.v.) at the following intervals during the I/R protocol; 15 minutes (n = 5/group) following the onset of MCAO, and 0, 30, 60, 90 minutes (n = 5, 6, 7, 4 respectively) following the onset of reperfusion.

Co-administration of Resveratrol and Lipoic Acid (tMCAO)

To examine neuroprotection following co-administration of various doses of resveratrol (2 × 10⁻³ mg/kg; i.v.) or vehicle (propylene glycol 4 × 10⁻³% (v/v); 1 ml/kg; i.v.) at the following intervals during the I/R protocol; 15 minutes (n = 5/group) following the onset of MCAO, and 0, 30, 60, 90 minutes (n = 5, 6, 7, 4 respectively) following the onset of reperfusion.

Delayed treatment effects were also studied by co-injecting resveratrol (2 × 10⁻³ mg/kg) and LA (0.005 mg/kg; i.v) at the...
following intervals during the I/R protocol: 15 minutes (n = 8) following the onset of MCAO, and 0, 30, 60, 90 minutes (n = 6, 6, 7, 4 respectively) following the onset of reperfusion.

**Co-administration of Resveratrol and Lipoic Acid and Permanent Occlusion (pMCAO)**

To determine if the co-administration of resveratrol and LA was neuroprotective on ischemia-induced cell death only, co-injection of resveratrol and LA (2×10^{-2} mg/kg and LA, 0.005 mg/kg; i.v.; n = 4) or vehicle (propylene glycol 4×10^{-3} (v/v); 1 ml/kg; i.v.; n = 4) were made 30 minutes prior to pMCAO. The experiments were terminated at the end of 6 hours of occlusion with no reperfusion period.

**UPEI-200 or 201 Effects in tMCAO or pMCAO**

The effects of UPEI-200 and UPEI-201 on infarct volume in both transient and permanent MCAO models were investigated. Dose-response curves were generated for both entities (n = 4–7/group). UPEI-201 was further studied for its effectiveness in delayed intervention by administering a neuroprotective dose (1×10^{-6} mg/kg) 15 minutes post-occlusion as well as 0, 30 and 60 minutes into the 5.5 hr reperfusion period (n = 4–7/group).

**Histological Procedures**

At the end of each experiment, in which infarct volume was measured, animals were transcardially perfused with phosphate buffered saline (PBS; 0.1 M; 200 mL). The brains were removed and sliced into 1 mm coronal sections with the aid of a rat brain matrix (Harvard Apparatus; Holliston, MA, USA). Sections were incubated in a 2% solution of 2,3,5-triphenol tetrazolium chloride (TTC; Sigma-Aldrich; St. Louis; MO, USA) for 5 minutes. Infarct volumes were calculated with measurements taken from scanned digital images of each brain section. The infarct area for opposing views of each brain section was calculated using a computer-assisted imaging system (Scion Corporation; Frederick, MD, USA), averaged and multiplied by section thickness (1 mm) to give a measure of infarct volume for each section. The sum total of the individual infarct volumes provided the infarct volume for each rat.
Co-administration of Resveratrol - Lipoic Acid and Apoptosis

In a separate set of experiments, the co-administration of resveratrol \( (2 \times 10^{-3} \text{ mg/kg}) \) and LA \( (0.005 \text{ mg/kg}; \text{i.v.; } n = 4) \) or vehicle \( (\text{propylene glycol; } 4 \times 10^{-3}\% \text{ (v/v); } 1 \text{ ml/kg; i.v.; } n = 4) \) were made 30 minutes prior to tMCAO. The sutures were left in place for 30 minutes followed by 5.5 hours of reperfusion. Animals were transcardially perfused with 200 mL of 0.1 M phosphate buffered saline (pH 7.4), the brains removed and the ipsilateral cerebral cortex isolated by careful dissection. A biopsy needle having an internal diameter of 8 mm was used to collect tissue from the region of infarct. The region of infarct was visually identified as that area which displayed a grayish hue and was slightly swollen compared to the surrounding healthy tissue. The biopsy needle was centered on this area and the tissue sample removed.

The tissue was weighed and homogenized (20% w/v) in ice cold PBS. The homogenate was centrifuged 12 000 \( \times g \) for 15 min at 4\(^\circ\)C. Aliquots of the supernatant were stored at –80\(^\circ\)C until assayed for protein. Apoptotic cell death was quantified using an ELISA based assay for determination of cytoplasmic histone-associated DNA fragments (Roche Diagnostics, Montreal, QC, CAN).

Statistical Analysis

Data were analyzed using a statistical software package (SigmaStat and SigmaPlot; Jandel Scientific, Tujunga, CA). All data are presented as a mean ± standard error of the mean (S.E.M). Differences were considered statistically significant if \( p \leq 0.05 \) by an analysis of variance (ANOVA) followed by a Bonferroni post-hoc analysis. When only two groups were being compared the Student’s t-test was used.

Results

Resveratrol and tMCAO

Pre-administration of resveratrol provided dose-dependent neuroprotection in our model of ischemia-reperfusion. This was
significant neuroprotection was observed when resveratrol (2 × 10⁻⁵ mg/kg) and LA (0.005 mg/kg) 30 minutes prior to 6 hours of permanent MCAO did not produce significant neuroprotection (p ≥ 0.05; data not shown).

The average infarct volumes following 6 hrs of permanent MCAO in the vehicle and resveratrol - LA treated groups were 25.3 ± 6 and 19.9 ± 3 mm³ respectively.

**UPEI-200 and UPEI-201 in tMCAO and pMCAO**

UPEI-200 is a chemical construct composed of 3 LA moieties bonded to a single resveratrol molecule (3:1). When administered 30 minutes prior to MCA occlusion in either tMCAO or pMCAO models, there was no significant neuroprotection observed at any of the doses tested (p ≥ 0.05; Fig. 5A, 5B).

Conversely, UPEI-201, which is composed of a single LA moiety bound to resveratrol (1:1), displayed potent neuroprotection when administered 30 minutes prior to MCA occlusion (Fig. 7A; p ≤ 0.05). Delayed intervention with UPEI-201 (1 × 10⁻⁶ mg/kg) was successful in reducing infarct volume when administered 15 minutes into the occlusion period (15 min; p ≤ 0.05, Fig. 8), but not when administered at the start or reperfusion or 30 minutes into the 3.5 hr reperfusion period (30, 60 min; Fig. 8).

**Effects of UPEI-201 on Blood Pressure and Heart Rate**

Since UPEI-201 was observed to provide neuroprotection in the tMCAO model, the following experiment was designed to determine the effect of UPEI-201 on arterial pressure and heart rate for a period of 2 hrs following administration. Baseline MAP and mean HR prior to drug administration were 109 ± 5 mm Hg and 372 ± 27 bpm, respectively. Intravenous administration of UPEI-201 (1 × 10⁻⁶ mg/kg; n = 4) did not significantly alter mean arterial blood pressure or mean HR at any time point during the 2 hrs of continuous recording compared with vehicle (n = 4; P ≥ 0.05; data not shown).

**Discussion**

Dietary plant phenolics such as resveratrol are being widely used in supplement form to prevent and treat common health concerns. Potential safety issues exist as high doses of resveratrol have been shown to cause renal toxicity [25] and contribute to hepatic oxidative stress [26]. In the presence of peroxidase and/or transition metals, resveratrol may function as a pro-oxidant contributing to DNA damage and mitochondrial dysfunction [27] [28]. As well, resveratrol has been shown to inhibit cytochrome P450 enzyme CYP1A1 [29], an interference which may render other drugs in a patient’s treatment plan ineffective at therapeutic doses. Clearly, the health benefits of resveratrol are extensive and hence, finding ways to harness the potency of resveratrol in the absence of adverse side effects is desirable.

To this end, we show in this study that resveratrol on its own produced dose-dependent neuroprotection against neuronal cell death in a rodent model of transient ischemia-reperfusion injury [24]. Combined injection of resveratrol with a non-neuroprotective dose of γ-lipoic acid [12] prior to tMCAO produced neuroprotection at doses of resveratrol 100 fold less than when injected alone. By chemically bonding resveratrol to lipoic acid in a 1:1 ratio (UPEI-201), we were able to show a further dose reduction (ten-fold lower) coincident with significant neuroprotection which supports the advantage of combination therapy in stroke treatment.

![Figure 8. Time course of the effect of UPEI-201 on infarct volume.](image-url)
Numerous studies have proven the efficacy of treatment with lipoic acid in disease states reflective of pro- and antioxidant imbalance such as diabetes, Alzheimer’s disease, cancer and cerebrovascular disease [30] [31] [32]. The chemical characteristics of LA, as well as its reduced form dihydrolipoic acid, qualify it as an effective scavenger of hydroxyl radicals, nitric oxide, peroxyl radicals and peroxynitrites, singlet oxygen species and hypochlorous acid [33]. Previously in our laboratory, we showed that LA pretreatment was effective as a neuroprotectant in both reperfusion injury following tMCAO [12] as well as in permanent ischemia (pMCAO) [13]. In the present study, combination of LA with resveratrol did not protect against neuronal death in a model of pMCAO. Prolonged ischemia is characterized by glutamate-induced neuronal toxicity ultimately leading to necrosis [3]. Generation of oxidative radicals is minimal owing to the lack of blood flow and dampening of mitochondrial activity, thereby rendering anti-oxidant therapy ineffectual. In contrast, antioxidants are highly effective in combating the oxidative stress generated during reperfusion injury which is demonstrated in the current study in our model of tMCAO. The reduction in infarct volume associated with resveratrol-LA treatment correlates with fewer necrotic cells at the ischemic core as evidenced with TTC staining, as well as reduced apoptotic cell death in the area of the penumbra as demonstrated by reduced oxidative DNA damage.

Other potential implications of combining resveratrol treatment with LA include their complementary participation in cell preserving pathways. For example, resveratrol and LA have both been shown to enhance aldehyde dehydrogenase-2-mediated detoxification of aldehydes in models of ethanol toxicity and ischemia-reperfusion injury respectively [4] [5]. Both compounds influence antioxidant status, in part through direct reduction of reactive oxygen species, but also as modulators of endogenous anti-oxidant systems. Resveratrol was shown to induce MnSOD activity in isolated rat liver mitochondria while LA inhibited glutathione peroxidase activity and induced mitochondrial uncoupling in the same model [34]. It is also noteworthy, that the LA/dihydrolipoate system is highly efficient in the reduction of the oxidized forms of antioxidants essentially aiding in their recycling allowing them to work more effectively without saturation [35]. Its dual solubility in water and lipid allows LA to interact with antioxidants in extracellular (blood) as well intracellular (both cytoplasmic and mitochondrial) compartments and to effectively cross the blood-brain barrier [36].

To utilize the strategy of combinatorial therapy, we created 2 new chemical entities, UPEI-200 and 201 and determined that a 1:1 ratio of resveratrol-LA moieties (UPEI-201) was preferred in providing neuroprotection following ischemia-reperfusion (tMCAO). UPEI-201 effectively provided neuroprotection when injected 15 minutes into the period of occlusion but not when injected during reperfusion. With dosing in the nanomolar range providing significant neuroprotection in our model of transient ischemia, UPEI-201 is clearly a potent neuroprotectant against oxidative damage. Future studies will be necessary to address mechanism of action, bioactivation, plasma stability, and pre-conditioning applications. Recent figures estimate medication non-compliance at around 50% at a cost of $300 hundred billion a year [37]. Novel compounds such as UPEI-201 which aim to provide multi-level care in a single dose, may improve compliance and could make a significant contribution to global health initiatives in treating and/or preventing cerebrovascular disease. In contrast, the ineffectiveness of UPEI-200 to provide neuroprotection in either tMCAO or pMCAO paradigms clearly demonstrates the utility of bioassay-guided optimization to achieve the ideal ratio of newly synthesized bioactive molecules.

In conclusion, the results presented above support the notion that combining antioxidants at subthreshold doses can produce equal or enhanced neuroprotective effects. In addition, creation of novel chemical entities via the synthetic bonding of these antioxidants can produce comparable effects to those observed by the co-administration of the 2 compounds, but at lower doses. The clear advantage to lowering the dose required to gain therapeutic effect is to minimize off-target effects on other organ systems which may lead to side effects as is seen in so many of the prescription drugs on the market today.

Author Contributions
Conceived and designed the experiments: TS MS BC AA BK DR IK. Performed the experiments: BC MS DR IK. Analyzed the data: BC TS MS IK DR. Contributed reagents/materials/analysis tools: DR IK AA BK. Wrote the paper: MS TS AA IK.

References


Copyright of PLoS ONE is the property of Public Library of Science and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.